Literature DB >> 28715767

Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants.

Elizabeth A Thompson1, Karin Loré2.   

Abstract

While transgenic mouse models are powerful for understanding how the immune system is manipulated by vaccines, they cannot fully recapitulate the characteristics of the innate immune responses leading to adaptive immunity after vaccination in humans. Outbred non-human primates are far more representative models of human vaccine responses as there is high degree of similarities in immune cell subset distributions, receptor expression (including toll-like receptors; TLRs), and immune cell functions, in addition to modeling doses and injection sites more accurately. Vaccine adjuvants targeting TLRs have shown great promise in their ability to enhance responses to non-live vaccines. As TLR ligands are molecularly defined, studies of the mechanisms by which they interact with the immune system are facilitated. In this brief review, we focus on the use of TLR3, 4, 7/8 and 9 stimulating adjuvants in NHPs by evaluating similarities between the specified TLRs in human and NHPs and highlighting recent work studying the mode of action or efficacy of TLR based adjuvants in NHPs.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28715767     DOI: 10.1016/j.coi.2017.06.006

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  17 in total

Review 1.  Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy.

Authors:  Qin Zeng; Christopher M Jewell
Journal:  Curr Opin Biotechnol       Date:  2019-03-01       Impact factor: 9.740

2.  Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.

Authors:  Caroline Petitdemange; Sudhir Pai Kasturi; Pamela A Kozlowski; Rafiq Nabi; Clare F Quarnstrom; Pradeep Babu Jagadeesh Reddy; Cynthia A Derdeyn; Lori M Spicer; Parin Patel; Traci Legere; Yevgeniy O Kovalenkov; Celia C Labranche; François Villinger; Mark Tomai; John Vasilakos; Barton Haynes; C Yong Kang; James S Gibbs; Jonathan W Yewdell; Dan Barouch; Jens Wrammert; David Montefiori; Eric Hunter; Rama R Amara; David Masopust; Bali Pulendran
Journal:  JCI Insight       Date:  2019-02-21

Review 3.  Biomaterials as Tools to Decode Immunity.

Authors:  Haleigh B Eppler; Christopher M Jewell
Journal:  Adv Mater       Date:  2019-11-29       Impact factor: 30.849

4.  Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity.

Authors:  Sebastian Ols; Lifei Yang; Elizabeth A Thompson; Pradeepa Pushparaj; Karen Tran; Frank Liang; Ang Lin; Bengt Eriksson; Gunilla B Karlsson Hedestam; Richard T Wyatt; Karin Loré
Journal:  Cell Rep       Date:  2020-03-24       Impact factor: 9.423

5.  Involvement of Toll-like Receptor 4 in Neutrophil-Mediated Inflammation, Oxidative Stress and Tissue Damage Induced by Scorpion Venom.

Authors:  Dalila Khemili; Fatima Laraba-Djebari; Djelila Hammoudi-Triki
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

6.  A novel vaccine adjuvant based on straight polyacrylate potentiates vaccine-induced humoral and cellular immunity in cynomolgus macaques.

Authors:  Vincent Pavot; Hélène Bisceglia; Florine Guillaume; Sandrine Montano; Linong Zhang; Florence Boudet; Jean Haensler
Journal:  Hum Vaccin Immunother       Date:  2021-01-10       Impact factor: 3.452

Review 7.  Chikungunya Virus Vaccines: Platforms, Progress, and Challenges.

Authors:  Victor R DeFilippis
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.291

8.  Vaccine nanodiscs plus polyICLC elicit robust CD8+ T cell responses in mice and non-human primates.

Authors:  Alireza Hassani Najafabadi; Zeynab Izadi Najaf Abadi; Marisa E Aikins; Kathryn E Foulds; Mitzi M Donaldson; Wenmin Yuan; Emeka B Okeke; Jutaek Nam; Yao Xu; Priyan Weerappuli; Taryn Hetrick; David Adams; Patrick A Lester; Andres M Salazar; Dan H Barouch; Anna Schwendeman; Robert A Seder; James J Moon
Journal:  J Control Release       Date:  2021-07-16       Impact factor: 11.467

9.  Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Mark T Orr; Susan Lin; Mohammed O Suraju; Adrian Simpson; Molly Blust; Tiep Pham; Jeffrey A Guderian; Mark A Tomai; James Elvecrog; Karl Pedersen; William A Petri; Christopher B Fox
Journal:  NPJ Vaccines       Date:  2018-06-05       Impact factor: 7.344

10.  TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25.

Authors:  Elizabeth A Thompson; Sebastian Ols; Kazutoyo Miura; Kelly Rausch; David L Narum; Mats Spångberg; Michal Juraska; Ulrike Wille-Reece; Amy Weiner; Randall F Howard; Carole A Long; Patrick E Duffy; Lloyd Johnston; Conlin P O'Neil; Karin Loré
Journal:  JCI Insight       Date:  2018-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.